01541.HK
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 3.15
−1.56%Margins
Gross margin
94.6%
EBITDA margin
-128.0%
EBIT margin
-134.8%
Net margin
-151.1%
FCF margin
-48.3%
-36.6%
Return on equity
-22.2%
Return on assets
-20.7%
Return on invested capital
0.14x
Asset turnover
-HKD 84.6M
Cash from operations
HKD 2.68
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026